Nasdaq exas.

Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. Exact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...

Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) was up 7.6% during trading on Friday . The company traded as high as $66.06 and last traded at $65.84. Approximately 1,116,388 shares changed hands during trading, a decline of 40% from the average daily volume of 1,860,572 shares. The stock had previously closed at $61.17.

In the quarter under review, Exact Sciences’ gross profit (excluding the amortization of acquired intangibles) rose 68% to $320.9 million. Gross margin expanded 276 basis points (bps) to 73.8% ...Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.Its recent ...

The company is scheduled to release Q3 earnings on November 3, 2022, after the market close. The market expects revenue of $503 million, a modest 10% YoY growth forecast. As EXAS starts shifting ...The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ...Exact Sciences EXAS stock price today per share is 67.03 USD. How to purchase Exact Sciences stock? You can buy EXAS shares on the NasdaqCM exchange. Contact ...

Jan 9, 2023 · A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...

EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

Exact Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off last year's report dates. Learn more on EXAS's earnings history.Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM ESTWebThe company is scheduled to release Q3 earnings on November 3, 2022, after the market close. The market expects revenue of $503 million, a modest 10% YoY growth forecast. As EXAS starts shifting ...Exact Sciences (NASDAQ: EXAS) Stock Quote. Follow Insider Trades Visit website. Last Trade: US$64.00 -1.06 -1.63. Volume: 1,800,029. 5-Day Change: -1.75%. YTD ...Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. 1. Exact Sciences. Exact Sciences' goal is to eradicate cancer. Perhaps that's too optimistic, but the company could play a role in reducing cancer deaths through its diagnostic solutions.

EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corporation Common Stock (EXAS) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.See the latest Exact Sciences Corp stock price (EXAS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. 2.68%. +0.25 0. ...

At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new October 28th contracts and identified one put and one call contract of particular ...Jul 25, 2023 · One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ... Board. Exact Sciences to participate in November investor conferences. November 01 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ...Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001.(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of ...11/02/2023 Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower. 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in ...Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...

Exact Sciences Corporation (NASDAQ:EXAS) is an extremely timely and compelling short, with an imminent catalyst that we believe will cause shares to plummet as much as 75% in the near future. EXAS ...

Earlier this month, Exact Sciences (NASDAQ: EXAS) announced extremely positive data regarding its multi-cancer blood test. Moreover, by using the test, health professionals were able to diagnose ...

EXACT SCIENCES CORP ( EXAS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ...Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03. ... 10 stocks we like better than Exact Sciences When o ur analyst team has a stock tip, ...NASDAQ:EXAS. Stock Report. EXAS. Exact Sciences. Stock Analysis. Analyst Forecasts. Technical Analysis. Options. New. Chart. Earnings. Dividends. Ownership. Financials. News & Insights ... Up to five ETFs with an Outperform Smart Score that hold EXAS. The ETFs are listed according to market value of EXAS within the ETF. …MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.20.11.23 NASDAQ Composite Index-Wert EXACT Sciences-Aktie: So viel Gewinn hätte eine EXACT Sciences-Investition von vor 10 Jahren eingebracht 06.11.23 …WebMay 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ... Fintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Exact Sciences world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA ...

The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... Apr 26, 2021 · Exact Sciences Corporation (NASDAQ: NASDAQ:EXAS) is a leader in global cancer screening and diagnostics undergoing rapid expansion through several new add-on acquisitions. According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The ...Instagram:https://instagram. apps for real estate investorsxc90 excellencemarket closedstocks below 50 About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995. learn how to buy and sell cryptocurrencyetrade metatrader Dec 16, 2022 · 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower. 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in ... Oct 9, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ... surge energy stock EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard ...Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.Web